A PHARMACOECONOMIC EVALUATION OF DRUGS IN PATIENTS OF PAINFUL DIABETIC NEUROPATHY

JASPINDER PRATAP SINGH; AASHISH SHARMA; Chetna Sharma

doi:10.22159/ajpcr.2023.v16i12.48426

Authors

JASPINDER PRATAP SINGH Department of Forensic Medicine and Toxicology, Government Medical College, Amritsar, Punjab, India. https://orcid.org/0000-0003-3510-4400
AASHISH SHARMA Department of Forensic Medicine and Toxicology, Government Medical College, Amritsar, Punjab, India.
Chetna Sharma Department of Pharmacology, Government Medical College, Amritsar, Punjab, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i12.48426

Keywords:

Diabetic neuropathy, Pharmacoeconomics, Visual analog scale score, Economic burden

Abstract

Objectives: To study the effect of methylcobalamin, the combination of methylcobalamin with pregabalin, and methylcobalamin with duloxetine in patients with painful diabetic neuropathy after comparing the safety, tolerability, and economic implications of all three study groups.

Methods: The present study was a prospective, open-labeled, interventional, randomized, and parallel-group study conducted on 100 patients of painful diabetic nephropathy from the outpatient department of the hospital who were recruited after obtaining informed consent. The permission for the study was taken from the Institutional Ethical Committee. The patients were randomized into three study groups: A, B, and C, on methylcobalamin, methylcobalamin, pregabalin, methylcobalamin, and duloxetine.

Results: The mean value of the price of each tablet from all the brands of the respective drugs and finally calculating the cost for the whole 3 months which comes out to be Rs. 797.4 for group A, Rs. 1940.4 for group B, and Rs. 1163.7 for group C. The cost of the entire treatment and the effect produced in terms of the difference in the visual analog scale score from day 1 to the end of week 12 which are 0.58 for group A, 3.82 for group b, and 4.17 for group C.

Conclusion: The primary purpose of the pharmacoeconomic evaluation is not to directly alter the therapeutic decisions of the physicians but to help the physicians, pharmacists, and policymakers to make informed decisions about whether the cost and extra benefits of the new drug are meaningful within the given budget.

Downloads

Download data is not yet available.

References

Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2008. p. 116-35, 217-36.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519

Bootman JL, Townsend RJ, Mcghan WF. Introduction to pharmacoeconomics. In: Principles of Pharmacoeconomics. Cincinnati, OH: Harvey Whitney Books Co.; 1996.

Scaria S, Raju R, Joseph S, Mohan A, Nair AA. Pharmacoeconomics: Principles, methods and Indian scenario. Int J Pharm Sci Rev Res 2015;34:37-46.

Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. Med Care 1996;34:DS89-95. PMID 8969317

Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract 2009;2:16-8.

Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984;5:115-28. doi: 10.1016/0197- 2456(84)90118-1, PMID 6430644

DiMasi JA. Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297-307. doi: 10.1067/mcp.2001.115446, PMID 11371997

Konuru V, Sangam K, Mohammed A, Kanneganti S. Evaluation of pharmacoeconomic direct cost in diabetes patients. Asian J Pharm Clin Res 2017;10:38-40. doi: 10.22159/ajpcr.2017.v10i4.8510

World Health Organization. Prevention of diabetes mellitus. Report of a WHO study group. World Health Organ Tech Rep Ser 1994;844:1- 100.

Robinson N, Lloyd CE, Stevens LK. Social deprivation and mortality in adults with diabetes mellitus. Diabet Med 1998;15:205-12. doi: 10.1002/ (SICI)1096-9136(199803)15:3<205:AID-DIA519>3.0.CO;2-#, PMID 9545121

Nilsson PM, Johansson SE, Sundquist J. Low educational status is a risk factor for mortality among diabetic people. Diabet Med 1998;15:213-9. doi: 10.1002/(SICI)1096-9136(199803)15:3<213:AID-DIA569>3.0. CO;2-#, PMID 9545122

Bellows BK, Dahal A, Jiao T, Biskupiak J. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother 2012;26:153-64. doi: 10.3109/15360288.2012.671240, PMID 22509775

Roy MK, Kuriakose AS, Varma SK, Jacob LA, Beegum NJ. A study on comparative efficacy and cost effectiveness of pregabalin and duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr 2017;11:31-5.

Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res 2007;7:189. doi: 10.1186/1472-6963-7-189, PMID 18028552

Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, et al. The economic costs of diabetes: A population-based study in Tehran, Iran. Diabetologia 2009;52:1520-7. doi: 10.1007/ s00125-009-1398-4, PMID 19475364

Rekik M, Abid M, Hachicha J, Abbes R, Moujahed M, Jarraya A. Direct cost of the ambulatory management of diabetes at the outpatient clinic of the national social security fund of Sfax (Tunisia). Bull World Health Organ 1994;72:611-4. PMID 7923540

Elrayah-Eliadarous H, Yassin K, Eltom M, Abdelrahman S, Wahlström R, Ostenson CG. Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan. Exp Clin Endocrinol Diabetes 2010;118:220-5. doi: 10.1055/s-0029-1246216, PMID 20140852

Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81:19-27. PMID 12640472

Currie CJ, Kraus D, Morgan CL, Gill L, Stott NC, Peters JR. NHS acute sector expenditure for diabetes: The present, future, and excess in-patient cost of care. Diabet Med 1997;14:686-92. doi: 10.1002/ (SICI)1096-9136(199708)14:8<686:AID-DIA434>3.0.CO;2-D, PMID 9272596

Beard SM, McCrink L, Le TK, Garcia-Cebrian A, Monz B, Malik RA. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008;24:385-99. doi: 10.1185/030079908x253852, PMID 18157921